API tools faq
paste
HRTU

Doxorubicin Hydrochloride

HRTU
Mar 24th, 2019
73
0
Never
Add comment
Not a member of Pastebin yet? Sign Up, it unlocks many cool features!
text 2.49 KB | None | 0 0
raw download clone embed print report
  1. Product Description
  2.  
  3. Doxorubicin Hydrochloride CAS 25316-40-9 for Antitumor Antibiotic
  4. Name: Doxorubicin hydrochloride
  5. CAS No.: 25316-40-9
  6. Formula: C27H30ClNO11
  7. Molecular Weight: 580.03
  8. EINECS: 246-818-3
  9. Melting Point: 216 °C (dec.)(lit.)
  10. Boiling Point: 810.3 °C at 760 mmHg
  11. Flash Point: 443.8 °C
  12.  
  13. Description
  14. It is a drug used in cancer chemotherapy. It is an anthracycline antibiotic, closely related to the natural product daunomycin, and like all anthracyclines, it works by intercalating DNA, with the most serious adverse effect being life-threatening heart damage. It is commonly used in the treatment of a wide range of cancers, including hematological malignancies, many types of carcinoma, and soft tissue sarcomas.
  15.  
  16.  
  17. Function
  18.  
  19. Use:Anti-mitotic and cytotoxic drugs. Doxorubicin can be successfully induced to alleviate a variety of malignancies, including acute leukemia, lymphoma, soft tissue and osteosarcoma, malignant tumors of children and adult solid tumors, especially for breast and lung cancer.
  20.  
  21. Usage
  22.  
  23. Doxorubicin hydrochloride (adriamycin hydrochloride) is an antitumor agent that has been formulated as a salt to achieve higher water solubility.While the salt shares the same pharmacological properties as doxorubicin free base, its greater water solubility may offer advantages in some in vitro applications.Physicochemical properties and chromatographic behaviour will depend on whether the ph is buffered.In non-ph controlled systems the free base and salt may behave differently.
  24. Packing:Foil bag or as required
  25.  
  26.  
  27.  
  28. Indication
  29.  
  30. As monotherapy for patients with metastatic breast cancer;
  31. For treatment of advanced ovarian cancer in women;
  32. In combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant;
  33. For treatment of AIDS-related Kaposi's sarcoma (KS) in patients with low CD4 counts and extensive mucocutaneous or visceral disease;
  34. may be used as first-line systemic chemotherapy, or as second line chemotherapy in AIDS-KS patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin.
  35.  
  36. ​contact information:
  37. Whatsapp:86-18873303856
  38. skype：live:d260a58b346fba38
  39. email：majorina.cai@chembj.com
  40. TEL:+86 18873303856​
Add Comment
Please, Sign In to add comment
Public Pastes
We use cookies for various purposes including analytics. By continuing to use Pastebin, you agree to our use of cookies as described in the Cookies Policy.  OK, I Understand
Not a member of Pastebin yet?
Sign Up, it unlocks many cool features!